Federal Circuit OKs Rejection Of ImmunoGen’s Cancer Patent Application
WASHINGTON, D.C. — A Federal Circuit U.S. Court of Appeals panel on March 6 affirmed a Virginia federal judge’s finding that a pharmaceutical company’s patent application for a treatment for ovarian...To view the full article, register now.
Already a subscriber? Click here to view full article